Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: SELL (auto-tracking)
-0.33% $15.24
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 963.58 mill |
EPS: | 2.20 |
P/E: | 6.93 |
Earnings Date: | May 06, 2024 |
SharesOutstanding: | 63.23 mill |
Avg Daily Volume: | 0.685 mill |
RATING 2024-03-28 |
---|
S |
Strong Buy |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Strong Buy | |
Return On Asset: | Strong Buy | |
DE: | Strong Buy | |
P/E: | Strong Buy | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE 6.93 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
1.18x |
Company: PE 6.93 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 14.81 - 15.67 ( +/- 2.85%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-05 | Basso Stephen | Buy | 25 899 | Non-statutory Stock Option |
2024-03-05 | Basso Stephen | Buy | 12 096 | Common Stock |
2024-03-05 | Ronsheim Matthew | Buy | 27 338 | Non-statutory Stock Option |
2024-03-05 | Ronsheim Matthew | Buy | 12 768 | Common Stock |
2024-03-05 | Zhen Marianne | Buy | 23 022 | Non-statutory Stock Option |
INSIDER POWER |
---|
89.89 |
Last 96 transactions |
Buy: 2 118 652 | Sell: 32 343 813 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $15.24 (-0.33% ) |
Volume | 0.450 mill |
Avg. Vol. | 0.685 mill |
% of Avg. Vol | 65.67 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | buy | $15.60 | N/A | Active |
---|
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.